Photo collage of Laura Bukavina and Phillip Abbosh
Jul 4, 2024, 13:06
Laura Bukavina: NTACT residual disease test presented by Phillip Abbosh
Laura Bukavina, Urologic Oncologist at Cleveland Clinic, shared on X:
“The NTACT residual disease test, eloquently presented by Phillip Abbosh published in JCO Precision Oncology. Remarkably, over 50% of patients without visible residual disease had positive mutations, indicative of field cancerization—mutations present in adjacent normal tissue WITHOUT cancer. NTACT demonstrated 91% sensitivity and 82% accuracy.”
Read further.
Source: Laura Bukavina/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 00:19
Nov 14, 2024, 00:02
Nov 13, 2024, 23:57
Nov 13, 2024, 23:54
Nov 13, 2024, 23:48
Nov 13, 2024, 23:46